Satsuma Pharmaceuticals, Inc. (STSA)
$1.1
0.00 (0.00%)
Rating:
Recommendation:
-
| Symbol | STSA |
|---|---|
| Price | $1.1 |
| Beta | 0.102 |
| Volume Avg. | 1.11M |
| Market Cap | 36.468M |
| Shares () | - |
| 52 Week Range | 0.59-8.08 |
| 1y Target Est | - |
| DCF Unlevered | STSA DCF -> | |
|---|---|---|
| DCF Levered | STSA LDCF -> | |
| ROE | 754.54% | Strong Buy |
| ROA | -145.67% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 0.31% | Neutral |
| P/E | -0.55 | |
| P/B | 0.97 | Buy |
Latest STSA news
About
Download (Excel)Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.